Since approval, DP had never had legitimate momentum in the wound care space. The financials/sales validate that fact. Without competitive reimbursement and a solid business plan (which has never been present), it's impossible to obtain traction and be competitive. Moreover, there are multiple like players in this tech space with much better leadership, direction, and pricing. On the flip, Mist is old technology, breaks down easily, and no company has produced a new unit since Alliqua.
The bottom line is the low single is where SNWV stock will live until sold off.
Market Data 
Markets 
AI
